Leonard van den Berg is professor of neurology and chairman of TRICALS. He is also director of The Netherlands ALS Center, which aims to improve the diagnosis, treatment/care and scientific research for ALS in the Netherlands. As chairman of the European Network to find the Cure for ALS (ENCALS), as initiator of the worldwide ALS genetics research Project MinE and as coordinator of awarded EU grants (FP7 Euro-MOTOR (systems biology) and JPND SOPHIA (biomarkers), he is strongly committed to international collaborations on ALS research.
He has been the principle investigator of multiple multicenter clinical trials and in 2015 he established the Treatment Research Initiative to Cure ALS to accelerate the search for a cure.
Connect
Connect trials
ATLAS study
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of ALS but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
PHOENIX trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound ‘AMX0035’ for the treatment of ALS.
ADORE Trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
COURAGE-ALS Trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
APL2-ALS-206 Trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
TUDCA-ALS
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.